“…In total, 250,000 hPDLSCs were seeded per well in 6-well plates using 3 mL DMEM supplemented with 10% FBS and 1% P/S. After 24 h incubation, hPDLSCs were stimulated with one of the following commercially available cytokines or TLRs: 100 ng/mL of human recombinant IFN-γ [ 25 , 36 ] (PeproTech, Rocky Hill, SC, USA), 10 ng/mL human recombinant TNF-α [ 25 , 37 ] (PeproTech, Rocky Hill, SC, USA), 5 ng/mL human recombinant IL-1β [ 25 , 38 ] (PeproTech, Rocky Hill, SC, USA), 1 µg/mL TLR-3 agonist Poly I/C [ 32 ] (Invivogen, San Diego, CA, USA) and 1 µg/mL TLR-2/1 agonist Pam3CSK4 [ 31 , 33 ] (Invivogen, San Diego, CA, USA). Stimulation was performed with 1 mL DMEM per well, supplemented with 1% P/S but without FBS.…”